Glendon J Parker

20110236918, Sep 29, 2011

Mar 24, 2011

13/071249

Glendon John Parker - Salt Lake City UT, US

C12Q 1/37

435 24

Methods and processes for conducting genetic analysis through protein polymorphisms, including identification of individuals, establishment of paternity and measurement of genetic diversity and distance. Some illustrative embodiments of methods of the present invention include the identification of peptide biomarkers using proteomic techniques, including liquid chromatography-tandem mass spectrometry from biological samples, using hair, dentin, or bone as a source of the protein to be analyzed. Other illustrative embodiments include the determination of allelic frequency and feasibility of protein polymorphism peptide biomarkers, and the application of these frequencies to allow statistical analysis and population genetics to be applied to collected biological samples.

20100166701, Jul 1, 2010

May 26, 2009

12/394038

Glendon John Parker - Salt Lake City UT, US

A61K 38/20
A61K 31/404
A61K 38/21
A61K 31/70

424 852, 514414, 424 857, 514 23

Renal cell carcinoma (RCC) exhibits unpredictable behavior, high recurrence rate, insensitivity to Positron-Emission Tomography (PET), and poor response to existing cancer treatments such as chemotherapy. Inhibition of glycogenolysis can restrict RCC tumor growth and increase its susceptibility to other treatments, in particular, those that compromise access to nutrient, such as anti-angiogenenic compounds. This can also increase uptake of glucose derivatives and thus increase sensitivity of PET. Reduction of glycogen stores within RCC through treatment with iron-salts can also reduce tumor growth rate through reducing activation of the hypoxia pathway. Thus, synergistic treatment of RCC with glycogenolysis inhibitors or inhibitors of glycogenosis, and/or in combination with anti-angiogenic compounds, can increase sensitivity of tumor detection, slow tumor formation and/or metastasis.